Absci to Participate on Synthetic Biology Enabling Drug Discovery Panel at Cowen 42nd Annual Health Care Conference
Absci Corporation (Nasdaq: ABSI) announced that CEO Sean McClain will participate in the Synthetic Biology Enabling Drug Discovery Panel at the Cowen 42nd Annual Health Care Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Absci Corporation (Nasdaq: ABSI) announced that CEO Sean McClain will participate in the Synthetic Biology Enabling Drug Discovery Panel at the Cowen 42nd Annual Health Care Conference. The event is set for March 8, 2022, from 12:30-1:30 p.m. Pacific Time / 3:30-4:30 p.m. Eastern Time. A live and archived webcast will be available on the company’s investor relations website.
Absci leverages deep learning AI and synthetic biology in drug discovery, aiming to advance the therapeutic potential of proteins.
Details
News Market Reaction – ABSI
The recorded move for ABSI in the trading session of this news was -0.96%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
VANCOUVER, Wash., March 01, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced that Sean McClain, CEO & Founder, will be participating on the Synthetic Biology Enabling Drug Discovery Panel at the Cowen 42nd Annual Health Care Conference.
The panel is scheduled to take place on March 8th, 2022 at 12:30-1:30 p.m. Pacific Time / 3:30-4:30 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the company’s investor relations website at: investors.absci.com.
About Absci
Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including those that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com, follow us on social media: Twitter: @Abscibio, LinkedIn: @absci, and subscribe to our Absci YouTube channel.
Availability of Other Information about Absci
Investors and others should note that we routinely communicate with investors and the public using our website (www.absci.com) and our investor relations website (investors.absci.com), including without limitation, through the posting of investor presentations, SEC filings, press releases, public conference calls and webcasts on these websites. The information that we post on these websites could be deemed to be material information. As a result, investors, the media, and others interested in Absci are encouraged to review this information on a regular basis. The contents of our website, or any other website that may be accessed from our website, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Investor Contact
investors@absci.com
Media Contact
press@absci.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.